IGF-1 LR3

Two Hormones, One Feedback Loop

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Growth hormone acts on the liver, which produces IGF-1, and circulating IGF-1 feeds back to suppress further growth hormone release. Many effects attributed to growth hormone are mediated by IGF-1 rather than by growth hormone acting directly.

Key facts

Sequence
Pituitary GH → liver → IGF-1
Feedback
IGF-1 suppresses GH release
In Laron syndrome
GH high, IGF-1 very low
Why
Feedback arm is absent
Liver as endocrine organ
Rhyu 2021 (PMID 34904032)
Related on this site
GHRH analogues and secretagogues

The sequence of events

The pituitary releases growth hormone in pulses. Growth hormone acts on hepatocytes, which produce IGF-1 and release it into circulation. IGF-1 then acts on peripheral tissues and also returns to the hypothalamus and pituitary, where it suppresses further growth hormone release. It is a classical endocrine loop with the liver as the middle step.

Why the intermediary matters

Many effects historically attributed to growth hormone are produced by IGF-1 rather than by growth hormone acting on the tissue directly. Growth hormone is in that sense partly an instruction to the liver, and the liver's product does much of the work. For that reason the two cannot be treated as interchangeable.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

What Laron syndrome does to the loop

It breaks the middle step. Growth hormone is produced and released normally but cannot be received, so IGF-1 production fails. Because IGF-1 is the feedback signal, its absence removes the brake and growth hormone rises further. The result is the characteristic combination of high growth hormone with very low IGF-1, a pattern that identifies the condition.

The liver as an endocrine organ

Rhyu and colleagues reviewed newly discovered endocrine functions of the liver in the World Journal of Hepatology in 2021. IGF-1 production is the long-established example, and it is a useful corrective to thinking of the liver purely as a metabolic and detoxifying organ. It is also a hormone-secreting tissue responding to a pituitary signal.

Why this connects to other compounds in this catalogue

Growth hormone releasing hormone analogues and growth hormone secretagogues act at the top of this loop, stimulating pituitary release. IGF-1 and its analogues act at the bottom, supplying the downstream mediator directly. They engage the same axis from opposite ends, and the feedback arm means an intervention at either end affects the other.

Why direct supply bypasses the regulation

Stimulating the pituitary produces IGF-1 through a loop that includes its own suppression: more IGF-1 means less growth hormone means less IGF-1. Supplying IGF-1 directly enters below that control point, so the feedback that would normally limit it is not engaged in the same way. That is a structural difference between acting at the top of an axis and acting at the bottom.

Quick reference

NormalLaron syndrome
Growth hormonePulsatile, regulatedHigh
GH receptorFunctionalDefective
IGF-1Produced by liverVery low
Feedback on GHPresentAbsent

Frequently asked questions

Does growth hormone act directly on tissues?

Partly, but many effects attributed to it are mediated by IGF-1, which the liver produces in response to it.

Why is growth hormone high in Laron syndrome?

IGF-1 is the feedback signal that suppresses it. Without IGF-1 production, that brake is absent.

How does this relate to GHRH analogues?

They act at the top of the loop by stimulating pituitary release; IGF-1 analogues act at the bottom by supplying the mediator directly.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.